Tumor radiosensitizers - Current status of development of various approaches: Report of an International Atomic Energy Agency meeting

Michael R. Horsman, Lothar Bohm, Geoffrey P. Margison, Luka Milas, Jean Francois Rosier, G. Sáfrány, Edgar Selzer, Marcel Verheij, Jolyon H. Hendry

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. Results: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. Conclusion: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.

Original languageEnglish
Pages (from-to)551-561
Number of pages11
JournalInternational Journal of Radiation Oncology Biology Physics
Volume64
Issue number2
DOIs
Publication statusPublished - Feb 1 2006

Fingerprint

Nuclear Energy
nuclear energy
tumors
Neoplasms
Developing Countries
drugs
Clinical Trials
gene therapy
Consultants
antibodies
Developed Countries
recommendations
toxicity
Pharmaceutical Preparations
Genetic Therapy
radiation therapy
therapy
Radiotherapy
cancer
Radiation

Keywords

  • IAEA
  • Meeting report
  • Radiosensitizers
  • Tumors

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Tumor radiosensitizers - Current status of development of various approaches : Report of an International Atomic Energy Agency meeting. / Horsman, Michael R.; Bohm, Lothar; Margison, Geoffrey P.; Milas, Luka; Rosier, Jean Francois; Sáfrány, G.; Selzer, Edgar; Verheij, Marcel; Hendry, Jolyon H.

In: International Journal of Radiation Oncology Biology Physics, Vol. 64, No. 2, 01.02.2006, p. 551-561.

Research output: Contribution to journalArticle

Horsman, Michael R. ; Bohm, Lothar ; Margison, Geoffrey P. ; Milas, Luka ; Rosier, Jean Francois ; Sáfrány, G. ; Selzer, Edgar ; Verheij, Marcel ; Hendry, Jolyon H. / Tumor radiosensitizers - Current status of development of various approaches : Report of an International Atomic Energy Agency meeting. In: International Journal of Radiation Oncology Biology Physics. 2006 ; Vol. 64, No. 2. pp. 551-561.
@article{f71aa072c0354c9b815720c685a52313,
title = "Tumor radiosensitizers - Current status of development of various approaches: Report of an International Atomic Energy Agency meeting",
abstract = "Purpose: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. Results: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. Conclusion: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.",
keywords = "IAEA, Meeting report, Radiosensitizers, Tumors",
author = "Horsman, {Michael R.} and Lothar Bohm and Margison, {Geoffrey P.} and Luka Milas and Rosier, {Jean Francois} and G. S{\'a}fr{\'a}ny and Edgar Selzer and Marcel Verheij and Hendry, {Jolyon H.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1016/j.ijrobp.2005.09.032",
language = "English",
volume = "64",
pages = "551--561",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Tumor radiosensitizers - Current status of development of various approaches

T2 - Report of an International Atomic Energy Agency meeting

AU - Horsman, Michael R.

AU - Bohm, Lothar

AU - Margison, Geoffrey P.

AU - Milas, Luka

AU - Rosier, Jean Francois

AU - Sáfrány, G.

AU - Selzer, Edgar

AU - Verheij, Marcel

AU - Hendry, Jolyon H.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Purpose: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. Results: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. Conclusion: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.

AB - Purpose: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. Results: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. Conclusion: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.

KW - IAEA

KW - Meeting report

KW - Radiosensitizers

KW - Tumors

UR - http://www.scopus.com/inward/record.url?scp=30544450340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30544450340&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2005.09.032

DO - 10.1016/j.ijrobp.2005.09.032

M3 - Article

C2 - 16414371

AN - SCOPUS:30544450340

VL - 64

SP - 551

EP - 561

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -